Ausgabe 3/2022
Drug Allergy
Inhalt (12 Artikel)
Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
Jamie L. Waldron, Stephen A. Schworer, Mildred Kwan
Hypersensitivity Reactions to Platinum Agents and Taxanes
Lulu R. Tsao, Fernanda D. Young, Iris M. Otani, Mariana C. Castells
Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics
Ellen Minaldi, Elizabeth J Phillips, Allison Norton
Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole
Michelle Dilley, Bob Geng
Nickel Hypersensitivity to Atrial Septal Occluders: Smoke Without Fire?
Anastasios Apostolos, Maria Drakopoulou, Stamatios Gregoriou, Andreas Synetos, George Trantalis, Georgios Tsivgoulis, Spyridon Deftereos, Konstantinos Tsioufis, Konstantinos Toutouzas
Drug Allergy Delabeling Programs: Recent Strategies and Targeted Populations
Karen M. Anstey, Lulu Tsao, Iris M. Otani
Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides
Linda J. Zhu, Anne Y. Liu, Priscilla H. Wong, Anna Chen Arroyo
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Anna Kychygina, Myriam Cassagne, Marie Tauber, Stéphane Galiacy, Carle Paul, Pierre Fournié, Michel Simon
Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review
ALMuhizi Faisal, Leticia De Las Vecillas Sanchez, Lucy Gilbert, Ana M. Copaescu, Ghislaine A. C. Isabwe
The Role of Patch Testing in Evaluating Delayed Hypersensitivity Reactions to Medications
Carina M. Woodruff, Nina Botto